8-K current report · filed Aug 3, 2026

Autolus Therapeutics plc (AUTL) 8-K Current Report: August 3, 2026

Item 8.01Item EX-99.1Item 2.02AUTL overview

Short answer

Autolus Therapeutics plc (AUTL) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release updates 2026 net product revenue guidance for AUCATZYL®.

Autolus Therapeutics plc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release updates 2026 net product revenue guidance for AUCATZYL®
  • Anticipated Q2 2026 AUCATZYL net product revenue disclosed
  • First-half 2026 anticipated AUCATZYL gross margin percentage disclosed
  • New credit facility and cash runway position announced as financing indicators

Item 8.01 · Other Events

  • 2026 AUCATZYL net revenue guidance raised to $140 million to $150 million from $120 million to $135 million
  • Guidance implies stronger commercial uptake and raises near-term revenue expectations
  • Cash, equivalents and marketable securities expected to fund operations into Q2 2028
  • Cash runway depends on anticipated AUCATZYL revenue and credit-facility proceeds
  • Outlook remains exposed to commercialization, regulatory, manufacturing and clinical-development risks

Item EX-99.1 · Exhibit EX-99.1

  • Preliminary Q2 AUCATZYL net revenue approximately $45 million, up approximately 70% versus Q1 2026 and more than 100% year over year
  • FY2026 sales guidance raised to $140 million-$150 million from $120 million-$135 million, signaling stronger commercial uptake
  • Gross margin approximately 35% year-to-date, reversing from approximately negative 20% in H2 2025
  • $75 million funded under a five-year, interest-only facility, with total borrowing capacity up to $250 million
  • Facility priced at one-month SOFR, subject to a 3.50% floor, plus 7.25%, with warrants for 3.5 million ADSs at $1.9314 each

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Autolus Therapeutics plc 8-K filings

Get the next AUTL 8-K as it lands

Follow AUTL for push alerts, or ask the research agent what this filing means.